Trends in FDA Medtech Regulatory Environment · EvaluateMedTech World Preview 2015, Outlook to 2020...
Transcript of Trends in FDA Medtech Regulatory Environment · EvaluateMedTech World Preview 2015, Outlook to 2020...
Copyright © 2015 Evaluate Ltd. All rights reserved.
Trends in FDA Medtech Regulatory Environment: 2014 Recap and 2015 YTD activity
Debbie Paul, CEO Americas, EvaluatePharma, USA Inc.
December 9, 2015
Copyright © 2015 Evaluate Ltd. All rights reserved.
Agenda
• About Evaluate
• Overview of data sources
• Review of key industry trends for 2020
• Review of FDA approvals in 2014 versus historic trends
• Assessment of FDA approvals for 2015
• Rundown of interesting 2015 findings
• Check-up on regional activity
• Summary
Copyright © 2015 Evaluate Ltd. All rights reserved.
About Evaluate
• Founded in 1996 by Dr. Jonathan de Pass, Headquarters in London, UK
• Offices in Boston, San Francisco and Tokyo
• A life science market analytics and intelligence company, known for its
consensus sales forecasts – became a gold-standard benchmark
• Three premier services
– EvaluatePharma®
– EvaluateClinical Trials®
– EvaluateMedTech®
» standardizes & integrates Devices@FDA data for easy tracking & screening
– Plus Custom Analytical & Technical Services
• Award winning editorial team of EP Vantage write daily commentary and analysis
including special reports
Copyright © 2015 Evaluate Ltd. All rights reserved.
EvaluateMedTech World Preview 2015, Outlook to 2020
• 2014 Commercial Analysis
• Consensus sales forecasts of the
top 20 companies in 2020
• Device Segment Forecasts to 2020
• R&D spend current and future
• FDA approvals
• M&A, Venture financing
• IPO Analysis
• Complimentary copies can be downloaded at:
www.evaluategroup.com/MedtechWP2015
Author: Ian Strickland, Product Manager EvaluateMedTech
Copyright © 2015 Evaluate Ltd. All rights reserved.
EP Vantage reports: 2014 Medtech Full Year Review & & 2015 Medtech Half Year Review
• Access EP Vantage complimentary reports and articles available at:
http://www.evaluategroup.com/public/NewsAndInsight.aspx
Authors: Elizabeth Cairns & Madeleine Armstrong, EPVantage journalists
Copyright © 2015 Evaluate Ltd. All rights reserved.
Top 10 Device Areas in 2020
6
• In Vitro Diagnostics projected to be the number one device area in 2020
Note: not shown on chart is Neurology, ranked 15th device area by revenue with the largest growth rate of 6.9%
Copyright © 2015 Evaluate Ltd. All rights reserved.
Top 10 Companies in 2020 by Worldwide Medtech Revenues
7
• Medtronic forecast to be the number one medtech company in 2020, following its acquisition of Covidien in January 2015
• 2020 sales expected to reach $34.9bn (7.3% share of entire medtech market at $478 bn)
Copyright © 2015 Evaluate Ltd. All rights reserved.
Top 10 Companies in 2020 by Worldwide Medtech R&D Spend
8
• Medtronic also forecast to take the number one spot from Johnson & Johnson for R&D spend in 2020
Note:
• Only Stryker & Danaher from the list of top 10 companies by revenue are not included in top for R&D spend
• Boston Scientific & St. Jude Medical are not included in top 10 by revenue but are in the top 10 by R&D spend
Copyright © 2015 Evaluate Ltd. All rights reserved.
Increases in All FDA Medtech Approvals in 2014 vs. 2013
9
• PMAs & HDEs Up 43% to 33 total in 2014
• 510(k) Clearances up 5% to 3,244 hitting a peak since 2007
• Supplementary PMAs up 5% to 2,455 also hitting peak since 2007
Copyright © 2015 Evaluate Ltd. All rights reserved.
Medtronic Again has Highest Number of Approvals & Clearances in 2014, with 831…
10
…more than double the number obtained by Boston Scientific, in second place with 396
Note: Top 10 companies account for 1/3 of all PMAs or 11 of 33
Copyright © 2015 Evaluate Ltd. All rights reserved. Copyright © 2015 Evaluate Ltd. All rights reserved. 11
2015 YTD Medtech
Copyright © 2015 Evaluate Ltd. All rights reserved.
2015 First PMA & HDE Approvals already higher than 2014
12
• 2015 could see the most device approvals in a decade
• 45 1st PMA & HDE approvals currently through November
Nov 2015
Projected 2015 total
X
Copyright © 2015 Evaluate Ltd. All rights reserved.
First PMA & HDE Approval Times in H1 2015 Highlights by the Numbers
• 17.1 months: the average PMA approval time in H1 2015 vs. 16.7 months in 2014
– however a significant improvement over the 26.9 months approval time in 2013
• 14.7 months: the average HDE approval time in H1 2015, beating the 17.1 for PMAs – however, there were only 2 HDEs in this time period:
− Kaneka’s Lixelle, a blood filter used to treat a rare protein-folding condition associated with chronic kidney failure, took more than two years to gain its HDE
− Abiomed’s Impella RP right-side heart pump got its HDE after just 4.4 months
• 10 devices granted De Novo clearance in H1 2015 with average approval time under 12 months
13
Copyright © 2015 Evaluate Ltd. All rights reserved.
First-time PMAs & HDEs by Therapy Area from 2013 to H1 2015
14
The sector with most approvals was cardiology: 11 approvals for heart
devices in H1 2015, or same as total in 2014
Copyright © 2015 Evaluate Ltd. All rights reserved.
Average Review Times for PMAs & HDEs by Therapy Area
15
• Cardiology devices got the go-ahead in average of 15.2 months in H1 2015, vs. overall average of 17.1 months
• Only imaging devices & wound management products were faster
Copyright © 2015 Evaluate Ltd. All rights reserved.
Rising Stars H1 2015
16
Abiomed (Danvers, MA)
• Heart pump developer Abiomed’s shares jumped
73% in the first six months of 2015 after US
approval of its first Impella RP temporary heart
pump and then its flagship Impella 2.5 device.
• Combined, these could bring in peak sales of $3bn
a year, according to some of the more optimistic
analysts.
Share Price Market Cap (B)
YE 2014 H1 2015 Change H1 2015 6M Change
Abiomed $38.06 $65.73 73% 2.743 1.187
Abiomed’s closing share price on 12/7/15 at $79.82 with market cap of $3.386 B
Copyright © 2015 Evaluate Ltd. All rights reserved.
Rising Stars H1 2015
17
DexCom (San Diego, CA)
• DexCom received FDA clearance via the De Novo
route for first system of mobile medical apps for
continuous glucose monitoring.
• The Share Direct Secondary Displays enable care
providers and doctors to track a patient’s blood
sugar levels.
• Excitement over the much-vaunted artificial
pancreas, a field in which DexCom is
collaborating, has no doubt helped the company’s
stock more than double in the past 18 months.
Share Price Market Cap (B)
YE 2014 H1 2015 Change H1 2015 6M Change
DexCom $55.05 $79.98 45% 6.342 2.127
DexCom’s closing share price on 12/7/15 at $87.23 with market cap of $7.091B
Copyright © 2015 Evaluate Ltd. All rights reserved.
Business Activity in the “Spot-light” with potential to impact future regulatory filings
18
• DENTSPLY announcing the acquisition of Sirona Dental for $5.6 billion in stock in September 2015 was the last big merger
• The single biggest M&A trend this year was probably the various mitral valve technology purchases by the following companies:
− Boston Scientific
− HeartWare
− Medtronic
− Abbott Laboratories
− Edwards Lifesciences
• 2015 has seen limited early venture funding
− Shrinking investment values in seed funding and series A & B rounds continue as a downward trend
Copyright © 2015 Evaluate Ltd. All rights reserved. Copyright © 2015 Evaluate Ltd. All rights reserved. 19
Regional Analysis
Copyright © 2015 Evaluate Ltd. All rights reserved.
2014: 510(k) Clearances Regional Analysis
20
• California had most 510(k) Clearances in 2014 with 541 (21%)
• Massachusetts second with 226 (9%)
2014 510(k) Clearances By State
541
226
159
158 156
1303
CA
MA
PA
FL
MN
Other
Copyright © 2015 Evaluate Ltd. All rights reserved.
2015 YTD: 510(k) Clearances Regional Analysis
21
• California has most 510(k) Clearances YTD 2015 with 428 (23%)
• Massachusetts second with 151 (8%)
2015 YTD 510(k) Clearances By State
428
151
123
120 108
948
CA
MA
FL
MN
PA
Other
Copyright © 2015 Evaluate Ltd. All rights reserved.
2014: Massachusetts 510(k) Clearances by Therapy Area
22
• Total of 226 in 2014 with FDA Review Time average of 4.6 months
2014 MA 510(k) Clearances By Therapy Area
36
29
18
16 15
112
General & Plastic Surgery
Cardiology
Dental
Nephrology
Diagnostic Imaging
Other
Copyright © 2015 Evaluate Ltd. All rights reserved.
2015 YTD: Massachusetts 510(k) Clearances by Therapy Area
23
• Total of 151 through Nov 2015 with FDA Review Time average of 4.1 months
2015 YTD MA 510(k) Clearances By Therapy Area
30
21
19 14
9
58
General & Plastic Surgery
Orthopedics
Cardiology
Dental
Diagnostic Imaging
Other
Copyright © 2015 Evaluate Ltd. All rights reserved.
Massachusetts 510(k) Clearances by Company
24
• Medtronic, Boston Scientific, J&J and AngioDynamics most active in MA
Company No. of 510(k)
Clearances
Percentage of YTD 2015
Total
Medtronic 11 7%
Boston Scientific 9 6%
Johnson & Johnson 9 6%
AngioDynamics 8 5%
Straumann 7 5%
YTD 2015 MA 510(k) Clearances By Company – Top 5 (151 total)
2014 MA 510(k) Clearances By Company – Top 5 (226 total)
Company No. of 510(k)
Clearances
Percentage of 2014 Total
Johnson & Johnson 18 8%
Boston Scientific 13 6%
Medtronic 13 6%
AngioDynamics 7 3%
Asahi Kasei/ ZOLL Medical 7 3%
Total 44
Total 58
Copyright © 2015 Evaluate Ltd. All rights reserved.
YTD 2015 Massachusetts HDE and First PMA Approvals
25
Company Product FDA Review
Time, Months Therapy Area
1st
PMA Abiomed 1. Impella 2.5 12.1 Cardiology
HDE Abiomed 2. Impella RP
System 4.4 Cardiology
1. 2.
Copyright © 2015 Evaluate Ltd. All rights reserved.
YTD 2015 Massachusetts 510(k) (De Novo) Approvals
26
Company Product FDA Review Time,
Months Therapy Area
Alcresta 1. Relizorb 10.6 Gastroenterology
Augmenix 2. SpaceOar System 6.0 Radiology
INVO Bioscience 3. Invocell 8.3 Obstetrics/Gynecology
1. 2.
3.
Copyright © 2015 Evaluate Ltd. All rights reserved.
Summary
27
• FDA productivity continues to improve with approval times decreasing even as submissions for medical technologies approvals are rising
• Total number of PMAs approved YTD 2015 is at peak rate over the past decade
• 1st ever system of mobile medical apps approved by the FDA for continuous glucose monitoring via De Novo route
• Massachusetts maintains its strong position with the 2nd most 510(k) clearances in 2014 & YTD 2015
A special thank you to Ian Strickland, Elizabeth Cairns and Madeleine Armstrong for their reports that this
presentation is based on and their contribution to finalizing this presentation.
Copyright © 2015 Evaluate Ltd. All rights reserved.
Thank you
Evaluate Headquarters
Evaluate Ltd.
11–29 Fashion Street
London E1 6PX
United Kingdom
T +44 (0)20 7377 0800
F +44 (0)20 7539 1801
Evaluate North America
EvaluatePharma USA Inc.
15 Broad Street, Suite 401
Boston, MA 02109, USA
T +1 617 573 9450
F +1 617 573 9542
Evaluate Japan K.K.
Akasaka Garden City 4F
4-15-1 Akasaka, Minato-ku
Tokyo 107-0052
Japan
T +81 (0)80 1164 4754
www.evaluate.com
Copyright © 2015 Evaluate Ltd. All rights reserved.
®
Debbie Paul
+1 617-573-9453